Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

February 6, 2026

Company name	Shin Nippon Biomedical Laboratories, Ltd.
Representative	Representative Chairman, President & CEO Ryoichi Nagata
Listing	TSE PRIME : ticker code 2395
Inquiries	Honorary Executive Director, Head of IR and Corporate Communications, Toshiyuki Iwata
TEL	+81 3 5565 6216

Notice Concerning Revisions to Full-Year Consolidated Financial Forecasts for the Fiscal Year Ending March 31, 2026

Based on recent business performance trends and other factors, Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, "the Company") hereby announces that the Company has revised consolidated full-year financial results forecasts announced on May 8, 2025, as follows.

1. Revisions to Consolidated Full-Year Financial Results Forecasts for the Current Fiscal Year (From April 1, 2025, to March 31, 2026)

	Revenue	Operating profit	Ordinary profit	Profit attributable to owners of parent	Profit per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous Forecasts (A)	33,272	3,550	5,927	3,550	85.27
Revised Forecasts (B)	30,698	2,600	5,353	3,561	85.53
Change (B - A)	(2,574)	(950)	(574)	11	
Change (%)	(7.7)	(26.8)	(9.7)	0.3	
ref.） Actual results of the previous fiscal year from April 1, 2024 to Marech 31, 2025	32,413	2,985	6,450	4,924	118.29

2. Reasons for the Revision

The main reason for the revision to full-year revenue forecast for the current fiscal year is that the recording of revenue in the nonclinical business is expected to be shifted partially to the next fiscal year or later due to delays in the provision of study compounds from clients and additions of studies in several large-scale projects. In the nonclinical business, as shown in the graph on the next page, orders received, which is a leading indicator of business performance, reached a record high of ¥10 billion in the third quarter from October to December 2025 on a quarterly basis, most of which will be booked as revenue in the next fiscal year and onwards.

Operating profit is expected to fall short of the initial plan by ¥950 million, partly due to a shift of recording of revenue explained above in the nonclinical business, which is the main source of revenue, and the second-half costs of ¥1,241 million incurred by the Company's US subsidiary, Satsuma Pharmaceuticals, Inc., despite the Company's efforts to offset them by reviewing expenses other than those of Satsuma in the TR business. Ordinary profit is revised downwardly to a lesser extent as share of profit of entities accounted for using equity method from PPD-SNBL K.K. exceeds the initial projection by ¥191 million. Profit attributable to owners of parent is revised slightly upwardly mainly due to lower income tax as a result of the flexible adjustment of the NHP (Non-human Primate) shipment volume from the Company's Cambodian subsidiary to Japan throughout the year.

Note: Projections above are based on information available to the Company at the time of disclosure of this document. Various risks and uncertain factors may cause actual results to differ materially from these projections.